litlas
Log inCreate account

Gerald S. Falchook

Active 2011–2025

Also published as
Gerald S Falchook
119
Papers
23,569
Citations
66
h-index
113
i10-index

Citations

Citations per year for Gerald S. Falchook1995: 1 citations1997: 1 citations2001: 1 citations2004: 2 citations2010: 2 citations2011: 16 citations2012: 95 citations2013: 301 citations2014: 349 citations2015: 333 citations2016: 278 citations2017: 286 citations2018: 230 citations2019: 662 citations2020: 929 citations2021: 1,354 citations2022: 1,280 citations2023: 1,127 citations2024: 1,560 citations2025: 940 citations2026: 34 citations1996: no citations, so this year is not shown1998–2000: no citations, so these years are not shown2002–2003: no citations, so these years are not shown2005–2009: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,531 citing papers, 28.6% of this breakdownChina: 1,434 citing papers, 11.6% of this breakdownItaly: 722 citing papers, 5.9% of this breakdownUnited Kingdom: 626 citing papers, 5.1% of this breakdownGermany: 574 citing papers, 4.7% of this breakdownFrance: 505 citing papers, 4.1% of this breakdownSpain: 431 citing papers, 3.5% of this breakdownAustralia: 397 citing papers, 3.2% of this breakdownJapan: 384 citing papers, 3.1% of this breakdownCanada: 325 citing papers, 2.6% of this breakdownNetherlands: 316 citing papers, 2.6% of this breakdownSwitzerland: 285 citing papers, 2.3% of this breakdown
0%28.6%Other 22.7%

Institutions

Fields

  • Medicine45.5%
  • Biochemistry, Genetics and Molecular Biology45.5%
  • Immunology and Microbiology4.2%
  • Computer Science1.2%
  • Chemistry1.1%
  • Materials Science0.5%
  • Other2%

Topics

  • Melanoma and MAPK Pathways5.4%
  • Lung Cancer Treatments and Mutations4.9%
  • Cancer Genomics and Diagnostics4.5%
  • Cancer Immunotherapy and Biomarkers4.5%
  • Colorectal Cancer Treatments and Studies2.7%
  • PI3K/AKT/mTOR signaling in cancer2.5%
  • Other75.5%

Coauthors

All papers

Open in search
  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

    Authors: Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy Price, Gerald S. Falchook, Jürgen Wolf, Antoîne Italiano, Martin Schüler, Hossein Borghaei, Fabrice Barlési, Terufumi Kato, Alessandra Curioni‐Fontecedro, Adrian G. Sacher, Alexander I. Spira, Suresh S. Ramalingam, Toshiaki Takahashi, Benjamin Besse, Abraham Anderson, Agnes Ang, Qui Tran, Omar Mather, Haby Henary, Gataree Ngarmchamnanrith, Gregory Friberg, Vamsidhar Velcheti, Ramaswamy Govindan - New England Journal of Medicine 2021 cited by 1,769

  2. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

    Authors: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan S. Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G. Knutson, Neelima Koppada, Brian A. Lanman, Jonathan Werner, Aaron S. Rapaport, Tisha San Miguel, Roberto Ortiz, Tao Osgood, Ji-Rong Sun, Xiaochun Zhu, John D. McCarter, Laurie P. Volak, Brett E. Houk, Marwan Fakih, Bert H. O’Neil, Timothy Price, Gerald S. Falchook, Jayesh Desai, James Kuo, Ramaswamy Govindan, David S. Hong, Wenjun Ouyang, Haby Henary, Tara Arvedson, Victor J. Cee, J. Russell Lipford - Nature 2019 cited by 2,303

  3. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    Authors: David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li - New England Journal of Medicine 2020 cited by 1,687

  4. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    Authors: David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi, Ho Yeong Lim, Andrew Brenner, Keunchil Park, Jae‐Lyun Lee, Tae‐You Kim, SangJoon Shin, Carlos Becerra, Gerald S. Falchook, Jay Stoudemire, Desiree Martin, Kevin Kelnar, Heidi J. Peltier, Vinícius Bonato, Andreas G. Bader, Susan Smith, Sinil Kim, Vincent O’Neill, Muhammad Shaalan Beg - British Journal of Cancer 2020 cited by 912

  5. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

    Authors: John H. Strickler, Hironaga Satake, Thomas J. George, Rona Yaeger, Antoine Hollebecque, Ignacio Garrido‐Laguna, Martin Schüler, Timothy F. Burns, Andrew L. Coveler, Gerald S. Falchook, Mark Vincent, Yu Sunakawa, Laëtitia Dahan, David L. Bajor, Sun Young Rha, Charlotte Lemech, Dejan Juric, Marko Rehn, Gataree Ngarmchamnanrith, Pegah Jafarinasabian, Qui Tran, David S. Hong - New England Journal of Medicine 2022 cited by 468

  6. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 cited by 836

  7. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    Authors: Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris - EClinicalMedicine 2021 cited by 275

  8. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    Authors: Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price - The Lancet Oncology 2021 cited by 288

  9. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Authors: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 cited by 2,798

  10. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

    Authors: Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S. Falchook, Antoîne Italiano, Jürgen Wolf, Adrian G. Sacher, Toshiaki Takahashi, Suresh S. Ramalingam, Christophe Dooms, Dong‐Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schüler, Pascale Tomasini, David S. Hong, Piro Lito, Qui Tran, Simon Jones, Abraham Anderson, Antreas Hindoyan, Wendy Snyder, Ferdinandos Skoulidis, Bob T. Li - Journal of Clinical Oncology 2023 cited by 149

  11. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

    Authors: Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet Ratti, Bianca Rojo, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, Kara Pekarek, Victoria H. Wu, Matthew Adamow, Scott McCauley, John B. Mumm, Phillip Wong, Peter Van Vlasselaer, Joseph A. Leveque, Nizar M. Tannir, Martin Oft - Cancer Cell 2018 cited by 251

  12. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

    Authors: Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric‐Bernstam - Clinical Cancer Research 2021 cited by 147

  13. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

    Authors: Kavanya Feustel, Gerald S. Falchook - Journal of Immunotherapy and Precision Oncology 2022 cited by 125

  14. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

    Authors: Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook, Eunice L. Kwak, David P. Ryan, Johanna C. Bendell, Omid Hamid, Wells A. Messersmith, Adil Daud, Razelle Kurzrock, Mariaelena Pierobon, Peng Sun, Elizabeth Cunningham, Shonda M Little, Keith Orford, Monica Motwani, Yuchen Bai, Kiran Klaus Patel, Alan P. Venook, Scott Kopetz - Journal of Clinical Oncology 2015 cited by 512

  15. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

    Authors: Elena Garralda, Ammar Sukari, Nehal J. Lakhani, Akash Patnaik, Yiyun Lou, Seock‐Ah Im, Talia Golan, Ravit Geva, Martin Wermke, M. de Miguel, J. Palcza, S. Jha, Marya Chaney, Anson K. Abraham, Jasmine Healy, Gerald S. Falchook - ESMO Open 2022 cited by 88

  16. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

    Authors: Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, Panli Cardona, Emily Chan, Tracy Varrieur, Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong - Nature Medicine 2024 cited by 89

  17. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    Authors: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 cited by 933

  18. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

    Authors: Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jiménez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey - Clinical Cancer Research 2022 cited by 97

  19. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

    Authors: Gerald S. Falchook, Antoni Ribas, Diwakar Davar, Zeynep Eroglu, Judy S. Wang, Jason J. Luke, Erika Hamilton, Brian Di Pace, Tianli Wang, Srimoyee Ghosh, Arindam Dhar, Theo Borgovan, Angela Waszak, Patricia LoRusso - Journal of Clinical Oncology 2022 cited by 75

  20. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

    Authors: Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel - Clinical Cancer Research 2022 cited by 78

  21. B7-H3 Inhibitors in Oncology Clinical Trials: A Review

    Authors: Kavanya Feustel, Jared Martin, Gerald S. Falchook - Journal of Immunotherapy and Precision Oncology 2023 cited by 73

  22. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Authors: Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith - The Lancet Oncology 2012 cited by 558

  23. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

    Authors: Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O’Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda S. Merchant, Gayle P. Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris F. Sachsenmeier - Clinical Cancer Research 2020 cited by 101

  24. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

    Authors: Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannová, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua K. Sabari, Sonya C. Chapman, Wei Zhang, Boris Calderón, Daniel A. Peterson - Investigational New Drugs 2021 cited by 58